Option Care Health Inc
NASDAQ:OPCH
Option Care Health Inc
Option Care Health Inc., nestled at the crossroads of healthcare services and cutting-edge pharmaceutical distribution, has carved a niche for itself in the burgeoning field of home and alternate-site infusion services. A pivotal player in this specialized sector, the company serves as a critical link between intricate medical therapies and the comfort of patients' homes. At its core, Option Care Health orchestrates a complex symphony of pharmaceuticals, skilled nursing, and patient convenience. By leveraging a network of healthcare professionals and state-of-the-art infusion pharmacies, the company enables patients requiring intravenous therapies for conditions ranging from chronic diseases to severe infections to receive care outside the traditional hospital setting. This model not only affords greater patient freedom and personalized care but also lends financial efficiencies to the healthcare system at large by reducing the need for expensive hospital stays.
Financially, the company's strength lies in its ability to integrate comprehensive health services with robust logistical operations. Option Care Health generates revenue primarily by billing insurers — including Medicare, Medicaid, and private insurance companies — for providing these specialized services. With an eye on scalability, the company continuously invests in technology and staff training to enhance operational efficiency and patient satisfaction. This strategic approach not only ensures high-quality care delivery but also fortifies its market position. By staying attuned to healthcare trends, such as the increasing demand for at-home medical care driven by an aging population and advancements in medical technology, Option Care Health retains its role as a forward-thinking entity poised for sustainable growth in an ever-evolving industry landscape.
Option Care Health Inc., nestled at the crossroads of healthcare services and cutting-edge pharmaceutical distribution, has carved a niche for itself in the burgeoning field of home and alternate-site infusion services. A pivotal player in this specialized sector, the company serves as a critical link between intricate medical therapies and the comfort of patients' homes. At its core, Option Care Health orchestrates a complex symphony of pharmaceuticals, skilled nursing, and patient convenience. By leveraging a network of healthcare professionals and state-of-the-art infusion pharmacies, the company enables patients requiring intravenous therapies for conditions ranging from chronic diseases to severe infections to receive care outside the traditional hospital setting. This model not only affords greater patient freedom and personalized care but also lends financial efficiencies to the healthcare system at large by reducing the need for expensive hospital stays.
Financially, the company's strength lies in its ability to integrate comprehensive health services with robust logistical operations. Option Care Health generates revenue primarily by billing insurers — including Medicare, Medicaid, and private insurance companies — for providing these specialized services. With an eye on scalability, the company continuously invests in technology and staff training to enhance operational efficiency and patient satisfaction. This strategic approach not only ensures high-quality care delivery but also fortifies its market position. By staying attuned to healthcare trends, such as the increasing demand for at-home medical care driven by an aging population and advancements in medical technology, Option Care Health retains its role as a forward-thinking entity poised for sustainable growth in an ever-evolving industry landscape.
Revenue Growth: Full-year 2025 net revenue was $5.6 billion, up 13% over the prior year, driven by balanced growth in both acute and chronic therapies.
In-line Results: Management reaffirmed that Q4 and full-year results were in line with January preannouncements and guidance.
Stelara Headwind: Revenue and gross profit faced a 160 basis point headwind from Stelara biosimilar adoption; impact was as expected, with a $20 million+ gross profit hit in Q4.
2026 Guidance Reaffirmed: Guidance for 2026 was reiterated, with revenue expected between $5.8 and $6 billion, adjusted EBITDA of $480–$505 million, and operating cash flow over $340 million.
Cash Flow Outlook: 2026 operating cash flow is expected to grow over 30% from 2025, with initiatives underway to reduce working capital needs.
Platform Expansion: The company opened new infusion suites and pharmacies, expanded its formulary, and grew its clinical and commercial teams, including investments in AI to automate claims processing.
M&A and Buybacks: Acquired Intramed Plus in 2025 (outperforming initial expectations), and repurchased over $300 million of shares; the buyback program was expanded by $500 million.
Acute & Chronic Trends: Acute revenue grew in the mid-teens and is expected to remain strong, while chronic therapies saw low double-digit growth, even with biosimilar headwinds.
